CDA | Evidence Driven
CDA | Evidence Driven

Tykerb Letrozole for Metastatic Breast Cancer - Details

Details

Files
Generic Name:
Lapatinib
Project Status:
Complete
Therapeutic Area:
Metastatic Breast Cancer
Manufacturer:
GlaxoSmithKline
Brand Name:
Tykerb (in combination with Letrozole)
Project Line:
Reimbursement Review
Project Number:
PC0019-000
Performance Metric:
N/A — Predated performance metrics
Strength:
250 mg
Tumour Type:
Breast
Indications:
Metastatic Breast Cancer
Funding Request:
In combination with letrozole for the treatment of postmenopausal patients with hormone receptor positive metastatic breast cancer, whose tumours overexpress the ErbB2 (HER2) receptor, and who are suitable for endocrine therapy
Review Status:
Complete
Sponsor:
GlaxoSmithKline
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Lapatinib (Tykerb) Letrozole for Metastatic Breast Cancer - pERC Final Recommendation Final Recommendation July 5, 2013 View PDF
Lapatinib (Tykerb) Letrozole for Metastatic Breast Cancer - Final Clinical Guidance Report Guidance Reports July 5, 2013 View PDF
Lapatinib (Tykerb) Letrozole for Metastatic Breast Cancer - Final Economic Guidance Report Guidance Reports July 5, 2013 View PDF
Lapatinib (Tykerb) Letrozole for Metastatic Breast Cancer - pERC Initial Recommendation Initial Recommendation May 2, 2013 View PDF
Lapatinib (Tykerb) Letrozole for Metastatic Breast Cancer - PAG Feedback on Initial Recommendation Feedback July 5, 2013 View PDF
Lapatinib (Tykerb) Letrozole for Metastatic Breast Cancer - Manufacturer (GSK) Feedback on Initial Recommendation Feedback July 5, 2013 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : July 22, 2013